Journey Medical Q2 EPS Forecast Reduced by HC Wainwright

Journey Medical Corporation (NASDAQ:DERM) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share (EPS) estimates for Journey Medical in a report issued on Thursday, May 14th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.07) for the quarter, down from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Journey Medical’s current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Journey Medical’s Q4 2026 earnings at $0.07 EPS and FY2026 earnings at ($0.05) EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $15.96 million for the quarter, compared to analysts’ expectations of $15.47 million. Journey Medical had a negative net margin of 14.82% and a negative return on equity of 35.57%.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Journey Medical in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Journey Medical has a consensus rating of “Hold” and a consensus target price of $13.00.

Journey Medical Stock Performance

Shares of Journey Medical stock opened at $6.25 on Tuesday. The company has a current ratio of 1.72, a quick ratio of 1.47 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $170.81 million, a P/E ratio of -16.89 and a beta of 1.03. The business has a fifty day simple moving average of $5.78 and a two-hundred day simple moving average of $7.28. Journey Medical has a 12 month low of $4.31 and a 12 month high of $9.56.

Hedge Funds Weigh In On Journey Medical

Several large investors have recently modified their holdings of the stock. Royal Bank of Canada raised its position in shares of Journey Medical by 42.7% in the 1st quarter. Royal Bank of Canada now owns 8,175 shares of the company’s stock worth $38,000 after purchasing an additional 2,446 shares during the last quarter. Pale Fire Capital SE raised its position in shares of Journey Medical by 8.4% in the 1st quarter. Pale Fire Capital SE now owns 481,987 shares of the company’s stock worth $2,261,000 after purchasing an additional 37,345 shares during the last quarter. Cetera Investment Advisers purchased a new position in shares of Journey Medical in the 1st quarter worth about $48,000. Bank of New York Mellon Corp raised its position in shares of Journey Medical by 29.4% in the 1st quarter. Bank of New York Mellon Corp now owns 37,195 shares of the company’s stock worth $174,000 after purchasing an additional 8,457 shares during the last quarter. Finally, Wasatch Advisors LP raised its position in shares of Journey Medical by 62.1% in the 1st quarter. Wasatch Advisors LP now owns 2,133,370 shares of the company’s stock worth $10,006,000 after purchasing an additional 817,095 shares during the last quarter. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.